| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2405433 | Vaccine | 2010 | 6 Pages |
Abstract
The incidence of hepatitis A infection in the United States has decreased dramatically in recent years because of childhood immunization programs. A decision analysis of the cost-effectiveness of hepatitis A vaccination for adults with hepatitis C was conducted. No vaccination strategy is cost-effective for adults with hepatitis C using the recent lower anticipated hepatitis A incidence, private sector costs, and a cost-effectiveness criterion of $100,000/QALY. Vaccination is cost-effective only for individuals who have cleared the hepatitis C virus when Department of Veterans Affairs costs are used. The recommendation to vaccinate adults with hepatitis C against hepatitis A should be reconsidered.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Michael K. Chapko, Helen S. Yee, Alexander Monto, Jason A. Dominitz,